The value of non-invasive tests for risk stratification in patients with compensated cirrhosis
Liver cirrhosis is characterized by a long compensatedphase, with a median survival from diagnosis of around12 years. When decompensation occurs (variceal bleeding,jaundice, hepatic encephalopathy or ascites) the expectedmedian survival is around two years [1,2]. Whereas there area number of well-validated scores for prognosis predictionand risk stratification in patients with decompensatedcirrhosis, these are very limited in the case of compensatedcirrhosis [1]. The two most widely validated prognosticfactors in compensated cirrhosis are the presence of clinicallysignificant portal hypertension (CSPH) [3], defined asa hepatic venous pressure gradient ≥10 mmHg, and thepresence of esophageal varices [1]. The gold standard teststo assess CSPH and varices are hepatic vein catheterismand endoscopy, respectively [4]. However, these tests,especially hepatic vein catheterism, are relatively invasiveand impractical for the frequent follow-up of these patients.This has fostered the interest in the use of non-invasive toolsfor the assessment of patients with compensated cirrhosis.
The value of non-invasive tests for risk stratification in patients with compensated cirrhosis
Liver cirrhosis is characterized by a long compensatedphase, with a median survival from diagnosis of around12 years. When decompensation occurs (variceal bleeding,jaundice, hepatic encephalopathy or ascites) the expectedmedian survival is around two years [1,2]. Whereas there area number of well-validated scores for prognosis predictionand risk stratification in patients with decompensatedcirrhosis, these are very limited in the case of compensatedcirrhosis [1]. The two most widely validated prognosticfactors in compensated cirrhosis are the presence of clinicallysignificant portal hypertension (CSPH) [3], defined asa hepatic venous pressure gradient ≥10 mmHg, and thepresence of esophageal varices [1]. The gold standard teststo assess CSPH and varices are hepatic vein catheterismand endoscopy, respectively [4]. However, these tests,especially hepatic vein catheterism, are relatively invasiveand impractical for the frequent follow-up of these patients.This has fostered the interest in the use of non-invasive toolsfor the assessment of patients with compensated cirrhosis.
___
- D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and
- prognostic indicators of survival in cirrhosis: a systematic
- review of 118 studies. J Hepatol 2006;44:217-31.
- D’Amico G, Pasta L, Morabito A, et al. Competing risks
- and prognostic stages of cirrhosis: a 25-year inception cohort
- study of 494 patients. Aliment Pharmacol Ther 2014;39:1180-
- Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous
- pressure gradient predicts clinical decompensation in patients
- with compensated cirrhosis. Gastroenterology 2007;133:481-
- Abraldes JG, Araujo IK, Turon F, Berzigotti A. Diagnosing
- and monitoring cirrhosis: Liver biopsy, hepatic venous
- pressure gradient and elastography. Gastroenterol Hepatol
- 35:488-95.
- Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers
- to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61.
- Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous
- pressure gradient predicts development of hepatocellular
- carcinoma independently of severity of cirrhosis. J Hepatol
- 50:923-8.
- Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO
- Atterbury CE, Glickman M. Portal pressure, presence of
- gastroesophageal varices and variceal bleeding. Hepatology
- 5:419-24.
- Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal
- hypertension in liver diseases. Expert Rev Gastroenterol
- Hepatol 2013;7:141-55.
- Rosselli M, MacNaughtan J, Jalan R, Pinzani M. Beyond
- scoring: a modern interpretation of disease progression in
- chronic liver disease. Gut 2013;62:1234-41.
- Castera L, Vergniol J, Foucher J, et al. Prospective
- comparison of transient elastography, Fibrotest, APRI, and
- liver biopsy for the assessment of fibrosis in chronic hepatitis
- C. Gastroenterology 2005;128:343-50.
- Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver
- stiffness measurement: a 5-year prospective study of 13,369
- examinations. Hepatology 2010;51:828-35.
- European Association for Study of L, Asociacion
- Latinoamericana para el Estudio del H. EASL-ALEH Clinical
- Practice Guidelines: Non-invasive tests for evaluation of liver
- disease severity and prognosis. J Hepatol 2015;63:237-64.
- Myers RP, Pomier-Layrargues G, Kirsch R, et al.
- Discordance in fibrosis staging between liver biopsy and
- transient elastography using the FibroScan XL probe. J
- Hepatol 2012;56:564-70.
- Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility
- and diagnostic performance of the FibroScan XL probe for
- liver stiffness measurement in overweight and obese patients.
- Hepatology 2012;55:199-208.
- Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness
- measurement predicts severe portal hypertension in patients
- with HCV-related cirrhosis. Hepatology 2007;45:1290-97.
- Groszmann RJ, Abraldes JG. Portal hypertension: from
- bedside to bench. J Clin Gastroenterol 2005;39:S215.
- Shi KQ, Fan YC, Pan ZZ, et al. Transient elastography: a
- meta-analysis of diagnostic accuracy in evaluation of portal
- hypertension in chronic liver disease. Liver Int 2013;33:62-
- Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen
- size, and platelet count identify portal hypertension in patients
- with compensated cirrhosis. Gastroenterology 2013;144:102-
- e101.
- Augustin S, Millan L, Gonzalez A, et al. Detection of early
- portal hypertension with routine data and liver stiffness in
- patients with asymptomatic liver disease: a prospective study.
- J Hepatol 2014;60:561-9.
- de Franchis R, Baveno VIF. Expanding consensus in
- portal hypertension: Report of the Baveno VI Consensus
- Workshop: Stratifying risk and individualizing care for portal
- hypertension. J Hepatol 2015;63:743-52.
- Takuma Y, Nouso K, Morimoto Y, et al. Measurement
- of spleen stiffness by acoustic radiation force impulse
- imaging identifies cirrhotic patients with esophageal varices.
- Gastroenterology 2013;144:92-101.
- Procopet B, Berzigotti A, Abraldes JG, et al. Real-time shearwave
- elastography: applicability, reliability and accuracy
- for clinically significant portal hypertension. J Hepatol
- 62:1068-75.
- Colecchia A, Montrone L, Scaioli E, et al. Measurement
- of spleen stiffness to evaluate portal hypertension and the
- presence of esophageal varices in patients with HCV-related
- cirrhosis. Gastroenterology 2012;143:646-54.
- Robic MA, Procopet B, Metivier S, et al. Liver stiffness
- accurately predicts portal hypertension related complications
- in patients with chronic liver disease: a prospective study.
- J.Hepatol 2011;55:1017-24.
- de Franchis R. Revising consensus in portal hypertension
- report of the Baveno V consensus workshop on methodology
- of diagnosis and therapy in portal hypertension. J Hepatol
- 53:762-8.
- Sherman M, Bilodeau M, Cooper C, et al. Liver Disease in
- Canada: A Crisis in the Making. In; 2013:1-70.
- D’Amico G. Natural History and Stages of Cirrhosis. In
- de Franchis R, Dell’Era A, eds. Variceal Hemorrhage: New
- York: Springer, 2014.
- Abraldes JG(1), Bureau C(2), Stefanescu H(3), Augustin S(4)
- Ney M(5), Blasco H(2), Procopet B(3,)(6), Bosch J(6,)(7)
- Genesca J(4), Berzigotti A(8,)(9); Anticipate Investigators.
- Non-invasive tools and risk of clinically significant portal
- hypertension and varices in compensated cirrhosis: The
- “Anticipate” study. Hepatology. 2016 Sep 17. doi: 10.1002/
- hep.28824.
- Kim BK, Han KH, Park JY, et al. A liver stiffness
- measurement-based, noninvasive prediction model for
- high-risk esophageal varices in B-viral liver cirrhosis. Am J
- Gastroenterol 2010;105:1382-90.
- Calvaruso V, Bronte F, Conte E, Simone F, Craxi A, Di
- Marco V. Modified spleen stiffness measurement by transient
- elastography is associated with presence of large oesophageal
- varices in patients with compensated hepatitis C virus
- cirrhosis. J Viral Hepat 2013;20:867-74.
- Villanueva C, Albillos A, Genesca J, et al. Development of
- hyperdynamic circulation and response to beta-blockers in
- compensated cirrhosis with portal hypertension. Hepatology
- 63:197-206.
- Reiberger T, Ferlitsch A, Payer BA, et al. Noninvasive
- screening for liver fibrosis and portal hypertension by
- transient elastography--a large single center experience.
- Wien Klin Wochenschr 2012;124:395-402.
- Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen
- size, and platelet count identify portal hypertension in patients
- with compensated cirrhosis. Gastroenterology 2013;144:102-
- Kitson MT, Roberts SK, Colman JC, Paul E, Button P, Kemp
- W. Liver stiffness and the prediction of clinically significant
- portal hypertension and portal hypertensive complications.
- Scand J Gastroenterol 2015;50:462-9.